{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EXTEND&page=13", "query": { "intervention": "EXTEND", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 5818, "total_pages": 582, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EXTEND&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EXTEND&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T13:33:05.340Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01117987", "title": "Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Arterial Hypertension" ], "interventions": [ { "name": "Imatinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 144, "start_date": "2010-04", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2015-08-13", "last_synced_at": "2026-10-18T13:33:05.340Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Weston", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01117987" }, { "nct_id": "NCT01493687", "title": "Phase 3 Papulopustular Rosacea Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Papulopustular Rosacea (PPR)" ], "interventions": [ { "name": "CD5024", "type": "DRUG" }, { "name": "Azelaic acid 15% Gel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Galderma R&D", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 683, "start_date": "2011-12", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2021-02-18", "last_synced_at": "2026-10-18T13:33:05.340Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Rogers, Arkansas • Los Angeles, California + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Ana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01493687" }, { "nct_id": "NCT00031733", "title": "Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intraocular Melanoma", "Melanoma (Skin)" ], "interventions": [ { "name": "MART-1 antigen", "type": "BIOLOGICAL" }, { "name": "gp100 antigen", "type": "BIOLOGICAL" }, { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" }, { "name": "recombinant interleukin-12", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "tyrosinase peptide", "type": "BIOLOGICAL" }, { "name": "alum adjuvant", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2002-02", "completion_date": "2007-11", "has_results": false, "last_update_posted_date": "2014-05-22", "last_synced_at": "2026-10-18T13:33:05.340Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00031733" }, { "nct_id": "NCT02221869", "title": "A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Narcolepsy With Cataplexy" ], "interventions": [ { "name": "Xyrem", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "7 Years to 17 Years" }, "enrollment_count": 106, "start_date": "2014-10-01", "completion_date": "2019-01-25", "has_results": true, "last_update_posted_date": "2019-04-30", "last_synced_at": "2026-10-18T13:33:05.340Z", "location_count": 17, "location_summary": "Long Beach, California • Orange, California • Redwood City, California + 14 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Redwood City", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02221869" }, { "nct_id": "NCT03955445", "title": "Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "C3 Glomerulopathy", "Immune-complex-membranoproliferative Glomerulonephritis" ], "interventions": [ { "name": "LNP023", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "12 Years to 100 Years" }, "enrollment_count": 225, "start_date": "2019-10-03", "completion_date": "2036-05-30", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-10-18T13:33:05.340Z", "location_count": 5, "location_summary": "Aurora, Colorado • Lawrenceville, Georgia • Iowa City, Iowa + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Lawrenceville", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03955445" }, { "nct_id": "NCT01596920", "title": "Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetic Foot Ulcers" ], "interventions": [ { "name": "Tissue", "type": "OTHER" }, { "name": "Control", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Osiris Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 97, "start_date": "2012-04", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2014-04-09", "last_synced_at": "2026-10-18T13:33:05.340Z", "location_count": 15, "location_summary": "Montgomery, Alabama • Glendale, Arizona • Encinitas, California + 12 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "Inverness", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01596920" }, { "nct_id": "NCT01875003", "title": "A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Lebrikizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 346, "start_date": "2013-08-13", "completion_date": "2016-12-28", "has_results": true, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-10-18T13:33:05.340Z", "location_count": 16, "location_summary": "Mission Viejo, California • Stockton, California • Aurora, Colorado + 12 more", "locations": [ { "city": "Mission Viejo", "state": "California" }, { "city": "Stockton", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Centennial", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01875003" }, { "nct_id": "NCT00601705", "title": "Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "epirubicin hydrochloride", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2008-01-05", "completion_date": "2015-01-23", "has_results": true, "last_update_posted_date": "2019-04-30", "last_synced_at": "2026-10-18T13:33:05.340Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00601705" }, { "nct_id": "NCT07385846", "title": "Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Mismatch Repair Deficiency" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Navifus Focused Ultrasound Sonification", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Jennifer Leddon", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2026-06-01", "completion_date": "2030-06-01", "has_results": false, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-10-18T13:33:05.340Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07385846" }, { "nct_id": "NCT00913627", "title": "Study Evaluating Ibuprofen 600 mg Extended Release (ER) For Dental Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pain" ], "interventions": [ { "name": "ibuprofen", "type": "DRUG" }, { "name": "naproxen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "16 Years to 40 Years" }, "enrollment_count": 196, "start_date": "2009-05-07", "completion_date": "2009-08-05", "has_results": true, "last_update_posted_date": "2018-03-22", "last_synced_at": "2026-10-18T13:33:05.340Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00913627" } ] }